Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 1Diarrhea 1

Interventions

pembrolizumab 245Nivolumab 141Cisplatin 137Cyclophosphamide 134Paclitaxel 115Carboplatin 108Gemcitabine 98Radiotherapy 84Dexamethasone 83Docetaxel 77atezolizumab 69Ipilimumab 67Fluorouracil 61Doxorubicin 61Blood Specimen Collection 59Bevacizumab 59Rituximab 55fludarabine 54Etoposide 53Oxaliplatin 52Lenalidomide 50Surveys and Questionnaires 49Prednisone 47Standard of Care 45Magnetic Resonance Spectroscopy 45Radiosurgery 44Cetuximab 44lenvatinib 43Capecitabine 43durvalumab 42

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Colesevelam Hydrochloride × 1 year × Clear all
NCT03767257 2025-10-21

A Study of Colesevelam for Lenalidomide-Associated Diarrhea

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
25 enrolled 6 charts
Plasma cell

Diarrhea, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡